These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


137 related items for PubMed ID: 888488

  • 1. [Metabolism of hexobarbital in patients with acute hepatitis and cirrhosis (author's transl)].
    Richter E, Gallenkamp H, Keller B, Brachtel D, Zilly W, Breimer DD.
    Z Gastroenterol; 1977 Jun; 15(6):381-8. PubMed ID: 888488
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Hexobarbital-oxidation in vivo and in vitro in rats after phenobarbital-pretreatment or after portacaval anastomosis (author's transl)].
    Richter E, Gallenkamp H, Brachtel D, Grün M.
    Z Gastroenterol; 1977 Jun; 15(6):389-92. PubMed ID: 888489
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of famotidine after intravenous administration in liver disease.
    Ohnishi K.
    Am J Gastroenterol; 1991 Jan; 86(1):41-5. PubMed ID: 1986553
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The effects of age and liver disease on the disposition and elimination of diazepam in adult man.
    Klotz U, Avant GR, Hoyumpa A, Schenker S, Wilkinson GR.
    J Clin Invest; 1975 Feb; 55(2):347-59. PubMed ID: 1127104
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Half-life time or clearance of indocyanine green in patients with liver disease.
    Gilmore IT, Marigold JH, Thompson RP.
    Hepatogastroenterology; 1982 Apr; 29(2):55-7. PubMed ID: 7084884
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Heme enhances hexobarbital metabolism in perfused rat liver after drug-mediated destruction of cytochrome P-450.
    Farrell GC, Gollan JL, Correia MA, Schmid R.
    J Pharmacol Exp Ther; 1981 Aug; 218(2):363-7. PubMed ID: 7252836
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Comparative study on the elimination of pindolol (visken) and antipyrin in patients with liver diseases].
    Ohnhaus EE, Münch U, Meier J.
    Schweiz Med Wochenschr; 1976 Dec 04; 106(49):1748-50. PubMed ID: 1013699
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Elimination of 75Se-selenmethionine from the plasma of patients with liver disorders (author's transl)].
    Pirwitz B.
    Przegl Lek; 1979 Dec 04; 36(7):573-6. PubMed ID: 504707
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Hexobarbital-oxidation in vivo and in vitro in rats with bile duct ligation or ANIT-cholestasis (author's transl)].
    Brachtel D, Gallenkamp H, Richter E.
    Z Gastroenterol; 1977 Jun 04; 15(6):378-80. PubMed ID: 888487
    [Abstract] [Full Text] [Related]

  • 19. Effect of manganese on hepatic drug metabolism in male and female rats.
    Schnell RC, Deimling MJ.
    Res Commun Chem Pathol Pharmacol; 1984 Feb 04; 43(2):307-15. PubMed ID: 6709965
    [Abstract] [Full Text] [Related]

  • 20. Enhanced renal clearance of uric acid in hepatic cirrhosis.
    Higuchi T, Nakamura T, Uchino H.
    Isr J Med Sci; 1981 Nov 04; 17(11):1015-8. PubMed ID: 7319788
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 7.